[A18-82] Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Last updated 01.03.2019
Project no.:
A18-82
Commission:
Commission awarded on 22.11.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with chronic lymphocytic leukaemia who are unsuitable for or have failed treatments with a B-cell receptor pathway inhibitor or chemoimmunotherapy
No comparisons with appropriate comparator therapy presented; added benefit neither proven for patients with 17p deletion or TP53 mutation nor for patients without 17p deletion or TP53 mutation
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-39 | Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-81 | Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G16-14 | Venetoclax (chronic lymphocytic leukaemia) – Assessment according to § 35a (para. 1, sentence 10) Social Code Book V | Commission completed |
| A21-82 | Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |